Orthopedic Surgery to Dominate the Biosurgery Applications Market

What This Report Will Provide?

This study involved four major activities in estimating the current size of the biosurgery market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market.

The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the size of segments and subsegments.

Expected Revenue Growth:

[314 Pages Report] The biosurgery market to reach $15.58 billion by 2023, at a CAGR of 6.5%.

Major Growth Boosters:

The major factors that are expected to be driving the biosurgery market are the rising geriatric population, increase in the volume of surgeries and sports-related and trauma injuries, increasing clearance of biosurgery products by regulatory authorities and growing need for effective blood loss management in patients.

Download PDF Brochure:

Recent Developments:

In April 2018, Medtronic plc received FDA approval for its infuse bone graft to use with additional spine implants made of polyetheretherketone (PEEK). This is specifically approved for spine, oral-maxillofacial, and orthopedic trauma surgeries.

In November 2017, Johnson & Johnson collaborated with Houston’s Texas Medical Center (US) to develop a facility for device innovation and to broaden the medical device product portfolio.

In July 2017, Baxter partnered with Tel Aviv University and Tel Aviv Sourasky Medical Center to bring new surgical innovations to the global market.

In February 2017, Integra LifeSciences Holding Corporation acquired the Johnson and Johnson’s business segment named Codman Neurosurgery. This segment broadened the portfolio of Integra and enhanced its position in the neurosurgery market.

Key Questions Addressed in The Report:

1. Who are the top 10 players operating in the global biosurgery market?
2. What are the drivers, restraints, opportunities, and challenges in the biosurgery Industry?
3. What are the opportunities for stakeholders and provide details of the competitive landscape for key players?
4. What will be growth of biosurgery in North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa?

Regional Growth Analysis:

North America is expected to hold the largest market size in the biosurgery market during the forecast period. The highest market share of North America is due to the presence of a well-developed healthcare system, increasing volume of surgical procedures performed, large number of hospitals, and presence of leading market players in the region. The Asia Pacific market is expected to witness the highest growth rate during the forecast period. The high growth in this market is attributed to the increasing prevalence of chronic diseases, increasing per capita income leading to improving standard of living, increasing healthcare spending, growing demand for better quality medical care, and rising awareness about biosurgery products in the region.

Request Sample Report:

Key Players:

Baxter International (US), Johnson & Johnson (J&J) (US), Medtronic plc (Ireland), Sanofi (France), C.R. Bard (US), Integra LifeSciences (US), and Maquet holdings (Sweden), lead the global biosurgery market. Some of the other leading players in this market include Cohera Medical (US), Hemostasis LLC. (US), Stryker Corporation (US), B.Braun Melsungen AG (Germany), CSL Limited (Australia), Pfizer Inc. (US), and Cryolife Inc. (US).